Clinical trials: Allogeneic Stem-Cell Transplant
Acute Myeloid Leukemia (AML), FLT3-ITD Mutation
MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib
The study population consisted of FLT3-ITD-mutated AML patients who were FLT3-ITD-positive before allogeneic hematopoietic stem cell transplantation.
- Conditions
- Acute Myeloid Leukemia (AML), FLT3-ITD Mutation, Allogeneic Hematopoietic Cell Transplantation (HCT), Maintenance Therapy
- Trial name
- TROPHY-15 (NCT07463651)
- Testing
- Gilteritinib, Sorafenib
- Where
- 2 sites in China
- Volunteers
- 594 people
- Sponsor
- The First Affiliated Hospital of Soochow University
GVHD
Comparison of Different Dose of Post-transplantation Cyclophosphamide as Graft Versus Host Disease Prophylaxis
Post-transplantation cyclophosphamide (PTCY) is considered as major graft versus host disease (GVHD) prophylaxis. In our previous study, the investigators demonstrated that the standard dose PTCY of 50mg/kg with tacrolimus and…
- Trial name
- NCT06000982
- Testing
- PTCY
- Where
- 2 sites in China
- Volunteers
- 138 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Hematopoietic Stem Cell Transplantation
Intrabone Infusion of Umbilical Cord Blood Stem Cells
The purpose of this study is to determine if the method of intrabone infusion of hematologic stem cells can increase and accelerate hematopoietic reconstitution after umbilical cord blood transplantation in pediatric patients.
- Trial name
- NCT01711788
- Testing
- Intrabone infusion of umbilical cord blood stem cells
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- Henrique Bittencourt, MD, PhD
Patients Receiving Mismatched Allogeneic HCT
Multicenter Study of Peritransplantation Immunosuppression for Mismatched Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
Feasibility and toxicity of peritransplantation immunosuppression with ATG, sirolimus, mycophenolate mofetil and rituximab in patients receiving mismatched allogeneic HCT after a reduced intensity conditioning regimen with…
- Trial name
- NCT01582048
- Testing
- immunosuppression
- Where
- 4 sites in Germany
- Volunteers
- 9 people
- Sponsor
- Prof. Dr. med. Wolfgang Bethge
Acquired Bleeding Disorder, Bleeding During/Following Surgery
Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation
This trial is conducted in Asia, Europe and Oceania. The aim of this trial is to evaluate the efficacy of placebo and activated recombinant human factor VII in patients having undergone allogeneic or autologous stem cell…
- Trial name
- NCT01562158
- Testing
- standard therapy, activated recombinant human factor VII
- Where
- 46 sites in United States, Australia and 14 more
- Volunteers
- 100 people
- Sponsor
- Novo Nordisk A/S
Leukemia, Lymphoma
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
Background: After an allogeneic hematopoietic stem cell transplant (HSCT), the donor genome is found in the recipient s circulation and tissues.
- Conditions
- Leukemia, Lymphoma, Hematologic Malignancy
- Trial name
- NCT06856226
- Testing
- Arm 1
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Haematological Malignancies, Allogeneic Stem Cell Transplant
CD56+CD3- NK Cells Following Allogeneic Stem Cell Transplantation
The investigators propose a nonrandomized, Phase I study to assess the safety of infusion of NK cells that will be selected from sibling donors and infused to patients with hematological malignancies early following allogeneic…
- Conditions
- Haematological Malignancies, Allogeneic Stem Cell Transplant, CD56+CD3- NK Cells
- Trial name
- NCT01336478
- Testing
- Infusion of donor derived ex-vivo selected NK cells to patients after transplant, Haematology / Blood chemistry sampling
- Where
- United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- Imperial College London
Pediatric Patients, Any Type of Severe Combined Immunodeficiency (SCID)
Safety and Efficacy Study of Human T Lymphoid Progenitor (HTLP) Injection After Partially HLA Compatible Allogeneic Hematopoietic Stem Cell Transplantation in SCID Patients
The purpose of this study is to evaluate the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after partially HLA compatible allogeneic hematopoietic stem cell…
- Conditions
- Pediatric Patients, Any Type of Severe Combined Immunodeficiency (SCID), Partial HLA Incompatible Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- Trial name
- HTLP Necker (NCT03879876)
- Testing
- Human T Lymphoid Progenitor (HTLP) injection
- Where
- France
- Volunteers
- 4 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Lymphoblastic Leukemia, Leukemia Acute Myeloid - AML
Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT
Allocation: Non-Randomized Endpoint Classification: Safety/Feasibility Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment Study to assess the feasibility and safety of the infusion of a T…
- Conditions
- Acute Lymphoblastic Leukemia, Leukemia Acute Myeloid - AML, Non-Hodgkin Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT01810120
- Testing
- TCR alfa beta T cell depletion
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Mariella Enoc
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Donor
Blood Samples to Identify Biomarkers in Patients Treated With Cyclophosphamide After Donor Stem Cell Transplant
This trial uses blood samples to understand how patients' bodies process and respond to a drug called cyclophosphamide given after a donor stem cell transplant.
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplant Recipient, Donor, Malignant Neoplasm
- Trial name
- NCT04160390
- Testing
- Biospecimen Collection-Blood, Biospecimen Collection-Stool
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Lymphoma
Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
RATIONALE: Giving chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00908180
- Testing
- alemtuzumab, donor lymphocytes, carmustine
- Volunteers
- 47 people
- Sponsor
- Cancer Research UK
Lymphoma
S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and melphalan, before a donor bone marrow or peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00121186
- Testing
- fludarabine phosphate, melphalan, methotrexate
- Where
- 33 sites in United States
- Volunteers
- 1 people
- Sponsor
- SWOG Cancer Research Network
Complication of Transplanted Organ, Nos
Autologous Hematopoietic Stem Cell Transplantation for Allogeneic Organ Transplant Tolerance
This open-label, proof-of-principle two center cohort study will evaluate the ability of autologous hematopoietic stem cell transplantation to induce tolerance in recipients of deceased or live donor liver transplants (ASCOTT).
- Trial name
- ASCOTT (NCT02549586)
- Testing
- Autologous Hematopoietic Stem Cell Transplant
- Where
- 2 sites in Canada
- Volunteers
- 5 people
- Sponsor
- Gary A Levy, O. Ont. MD. FRCP AGAF
Sickle Cell Disease
Comparison of Allogeneic Matched Related Haematopoietic Stem Cell Transplantation After a Reduced Intensity Conditioning Regimen With Standard of Care in Adolescents and Adults With Severe Sickle Cell Disease
Although the survival of children with sickle cell disease (SCD) has dramatically improved over the last decades in the US and Europe, mortality remains high in adults.
- Trial name
- DREPA-RIC (NCT04046705)
- Testing
- Allogeneic matched related haematopoietic stem cell transplantation, Standard arm
- Volunteers
- 78 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Kidney Cancer
Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Giving low doses of chemotherapy, such as cyclophosphamide and fludarabine, before a donor peripheral blood stem cell transplant helps stop the growth of tumor cells.
- Trial name
- NCT00003553
- Testing
- HLA Matched Peripheral BLood Stem Cells
- Where
- United States
- Volunteers
- 156 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Beta-Thalassemia Major, Graft-versus-host Disease (GVHD)
Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major
The purpose of this study is to evaluate the basiliximab for prevention of graft-versus-host disease in unrelated allo-genetic hematopoietic stem cell transplantation for thalassemia major.
- Trial name
- NCT02342145
- Testing
- Basiliximab,, Tacrolimus, Methotrexate
- Where
- 3 sites in China
- Volunteers
- 205 people
- Sponsor
- Zhongming Zhang
Hematologic Diseases
Allogeneic γ9δ2 T Cells Treatment of Recurrent Hematologic Tumors
This is an open single-arm clinical study aimed at evaluating the safety and tolerance of allogeneic γ9δ2 T cell injection in the treatment of patients with recurrent hematologic tumors after allogeneic hematopoietic stem cell…
- Trial name
- NCT05755854
- Testing
- allogeneic γ9δ2 T Cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Anhui Provincial Hospital
Acute Leukemia, High Risk, Myelodysplastic Syndromes, High Risk
A Study Testing an Improved Dose of UM171 to Help Make Cord Blood Transplants More Effective and Safe.
This clinical study is testing a new way to improve stem cell transplants for adults with high-risk blood cancers, such as leukemia or myelodysplasia, who do not have a suitable donor.
- Conditions
- Acute Leukemia, High Risk, Myelodysplastic Syndromes, High Risk, Hematologic Malignancy Requiring an Allogeneic Hematopoietic Stem Cell Transplant Lacking a Donor
- Trial name
- ECT-001-CB-013 (NCT07301866)
- Testing
- ECT-001-CB
- Where
- Canada
- Volunteers
- 7 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Lymphoma, B-cell, Lymphoma, Non-Hodgkin
Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
The purpose of this study is to determine if double autologous then allogeneic hematopoietic cell transplant may offer an improved treatment option for patients with relapsed diffuse large B-cell lymphoma (DLBCL) who are not…
- Conditions
- Lymphoma, B-cell, Lymphoma, Non-Hodgkin, Diffuse Large B-cell Lymphoma (DLBCL), Malignant Lymphoma, Non-Hodgkin
- Trial name
- NCT00482053
- Testing
- Autologous hematopoietic stem cell transplantation (auto-HSCT), Allogeneic hematopoietic stem cell transplantation (allo-HSCT), Total lymphoid irradiation (TLI)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Stanford University
Leukemia, Lymphocytic, Chronic, Leukemia, Lymphocytic, Acute
Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies
High dose chemotherapy followed by transplantation of allogeneic hematopoietic stem cell with the use of Campath-1h, a monoclonal antibody that have a synergistic effect to chemotherapy with minimal toxicity.
- Conditions
- Leukemia, Lymphocytic, Chronic, Leukemia, Lymphocytic, Acute, Lymphoma, Low-Grade, Lymphoma, T-Cell
- Trial name
- NCT00038883
- Testing
- Campath-1H
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.